Equity Details
Price & Market Data
Price: $13.95
Daily Change: -$0.47 / 3.37%
Daily Range: $13.53 - $14.49
Market Cap: $1,954,714,496
Daily Volume: 4,657,957
Performance Metrics
1 Week: 5.11%
1 Month: -1.89%
3 Months: 17.46%
6 Months: 46.95%
1 Year: 63.63%
YTD: 55.62%
About Intellia Therapeutics, Inc. (NTLA)
Your comprehensive guide to Intellia Therapeutics, Inc. (NTLA). Price: 13.95, daily change: -$0.47 / 3.37%. Market cap: 1,954,714,496. Full range of performance data for investors.
Company Details
Employees: 377
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.